NCT06795022 - First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

February 25, 2028

Study Completion Date

July 25, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

AZD9793 Intravenous (IV) monotherapy

T cell-engaging antibody that targets GPC3 on tumour cells

DRUG

AZD9793 Subcutaneous (SC) monotherapy)

T cell-engaging antibody that targets GPC3 on tumour cells

Trial Locations (16)

333

RECRUITING

Research Site, Taoyuan District

5505

RECRUITING

Research Site, Seoul

10002

RECRUITING

Research Site, Taipei

21201

NOT_YET_RECRUITING

Research Site, Baltimore

63108

RECRUITING

Research Site, St Louis

77030

RECRUITING

Research Site, Houston

90089

NOT_YET_RECRUITING

Research Site, Los Angeles

92093

NOT_YET_RECRUITING

Research Site, La Jolla

150049

NOT_YET_RECRUITING

Research Site, Harbin

201114

NOT_YET_RECRUITING

Research Site, Shanghai

510515

NOT_YET_RECRUITING

Research Site, Guangzhou

610041

NOT_YET_RECRUITING

Research Site, Chengdu

000000

RECRUITING

Research Site, Shatin

277-8577

NOT_YET_RECRUITING

Research Site, Kashiwa

241-8515

NOT_YET_RECRUITING

Research Site, Yokohama

06351

NOT_YET_RECRUITING

Research Site, Seoul